Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Conditions
Ovarian Carcinoma
Conditions: official terms
Carcinoma - Neoplasms, Glandular and Epithelial - Ovarian Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Overall Status
Recruiting
Summary
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Pre-Inclusion Criteria:

- Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT)

Inclusion Criteria:

- Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.

- Neo adjuvant chemotherapy

Exclusion Criteria:

- no neo-adjuvant chemotherapy

- no ovarian carcinoma at final pathological analysis

- less than 18 years old.
Location
Service de Gynécologie
Rennes, France
Status: Recruiting
Contact: Vincent Lavoué, PH - vincent.lavoue@chu-rennes.fr
Start Date
January 2015
Completion Date
January 2019
Sponsors
Rennes University Hospital
Source
Rennes University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page